Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Infliximab
Remicade
Not routinely available
NICE (TA329 (SMC 854/13))
17/04/2013

Indication

Treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

Treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

Therapeutic Area

Gastro-intestinal system

Status Description

Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines

Formulation

100mg powder for concentrate for solution for infusion

Comments

April 2013 - Not included on the LJF because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine. February 2015 - NICE MTA Advice: SMC Advice 854/13 is superseded by NICE TA329. April 2019 (as per LJF) - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.

Link to Advice

TA329 (SMC 854/13)

Advice Published

25/02/2015